Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane (paclitaxel protein-bound particles for injectable suspension).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
27 September 2016 India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.
27 September 2016 India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.
27 September 2016 India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.